Advertisement

Helicobacter pylori

  • G. M. A. Börsch
  • D. Y. Graham
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 99)

Abstract

The rediscovery of spiral shaped, Campylobacter-like gastric bacteria, later termed Campylobacter pylori (C. pylori), and in October 1989 renamed as Helicobacter pylori (H. pylori: Goodwin et al. 1989), has suddenly questioned the comprehensiveness of previous pathogenetic concepts in peptic ulcer disease. H. pylori finally offers an intriguing explanation to some of the puzzling complexities of this disease, e.g., why virtually all idiopathic, recurrent ulcers occur in the presence of chronic type B gastritis. H. pylori leaves other equally perplexing riddles unresolved, e.g., the fact that peptic ulcers are invariably a localized and periodic phenomenon, a finding obviously hard to correlate with a bacterial infection that is both diffuse and stable. Above all and for the first time, however, H. pylori has suggested the possibility of obtaining lasting cure rather than mere temporary control of ulcer disease, which would open a completely new era in the medical management of this condition.

Keywords

Duodenal Ulcer Pylorus Infection Peptic Ulcer Disease Ulcer Healing Eradication Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Al-Moagel MA, Evans DG, Abdulghani ME, Adam E, Evans DJ Jr, Malaty HM, Klein PD, Graham DY (1989) Comparison of the prevalence of C. pylori infection in individuals with and without upper gastrointestinal symptoms. Gastroenterology 96:A10.Google Scholar
  2. Alpert LC, Lew GM, Michaletz PA, Graham DY (1989) Effect of eradication of C. pylori on gastric function and structure. Gastroenterology 96:A10.Google Scholar
  3. Armstrong JA, Wee SH, Goodwin CS, Wilson DH (1987) Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro — an ultrastructural study. J Med Microbiol 24:343–350.PubMedGoogle Scholar
  4. Axon ATR (1990) Is nonulcer dyspepsia improved by treating Helicobacter pylori infection? In: Ditschuneit H, Malfertheiner P (eds) Helicobacter pylori, gastritis, and peptic ulcer. Springer, Berlin Heidelberg New York Tokyo, pp. 434–437.Google Scholar
  5. Bader JP (1987) The safety profile of De-NolR. Digestion [Suppl 2] 37:53–59.Google Scholar
  6. Bartlett JG (1988) Campylobacter pylori: fact or fancy? Gastroenterology 94:229–238.PubMedGoogle Scholar
  7. Bayerdörffer E, Ottenjann R (1988) The role of antibiotics in Campy lobacter pylori associated peptic ulcer disease. Scand J Gastroenterol [Suppl 142] 23:93–100.Google Scholar
  8. Bayerdörffer E, Kasper G, Pirlet T, Sommer A, Ottenjann R (1987a) Ofloxacin in der Therapie Campylobacter-pylori-positiver Ulcera duodeni. Dtsch Med Wochenschr 112:1407–1411.PubMedGoogle Scholar
  9. Bayerdörffer E, Simon T, Bästlein C, Ottenjann R (1987b) Bismuth/ofloxacin combination for duodenal ulcer. Lancet 2:1467–1468.PubMedGoogle Scholar
  10. Bayerdörffer E, Pirlet T, Sommer A, Kasper G, Ottenjann R (1988) Ofloxacin in der Therapie “resistenter” Ulcera duodeni. Eine Pilotstudie. Z Gastroenterol 26:155–159.PubMedGoogle Scholar
  11. Beard CM, Noller KL, O’Fallon WMO, Kurland LT, Dahlin DC (1988) Cancer after exposure to metronidazole. Mayo Clin Proc 63:147–153.PubMedGoogle Scholar
  12. Bianchi Porro G, Lazzaroni M (1988) Campylobacter pylori and ulcer recurrence. Lancet 1:593.PubMedGoogle Scholar
  13. Bianchi Porro G, Lazzaroni M (1989) Campylobacter pylori and peptic ulcer therapy. Gastroenterol Clin Biol 13:107B–111B.PubMedGoogle Scholar
  14. Blaser MJ (1987) Gastric Campylobacter-like organisms, gastritis, and peptic ulcer disease. Gastroenterology 93:371–383.PubMedGoogle Scholar
  15. Bohnen JMA, Krajden S, Anderson JGD, Kempston JD, Fuksa M, Karmall MA, Osborne A, Babida C (1986) Campylobacter pyloridis is associated with acid-peptic disease in Toronto. Can J Surg 29:442–444.PubMedGoogle Scholar
  16. Borody T, Cole P, Noonan S, Morgan A, Ossip G, Maysey J, Brandi S (1988) Long-term Campylobacter pylori recurrence post-eradication. Gastroenterology 94:A43.Google Scholar
  17. Borody T, Noonan S, Cole P, Hyland L, Morgan A, Lenne J, Moore-Jones D, Brandi S (1989) Duodenal ulcer recurrence in patients remaining C. pylori (CP) negative long term post-eradication. Gastroenterology 96:A52.Google Scholar
  18. Börsch G (1987) Campylobacter pylori: new and renewed insights into gastritis-associated ulcer disease (GAUD). Hepato gastroenterology 34:191–193.PubMedGoogle Scholar
  19. Börsch G (1988a) Therapie der Campylobacter pylori-lnfektion. Leber Magen Darm 18:40–45.Google Scholar
  20. Börsch G (1988b) Ulcera peptica: Assoziation mit der Campylobacter pylori-Besiedlung der Antrum-und Bulbusmukosa. In: Ottenjann R, Schmitt W (eds) Aktuelle Gastroenterologie — Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 101–115.Google Scholar
  21. Börsch G (1988c) Campylobacter pylori, Ulcus und Dyspepsie. Dtsch Med Wochenschr 113:1781–1782.PubMedGoogle Scholar
  22. Börsch G (1989a) Ist Campylobacter pylori der Erreger der Ulkuskrankheit? Z Gastroenterol 27:121–126.PubMedGoogle Scholar
  23. Börsch G (1989b) Clinical significance of Campylobacter pylori. Eur J Gastroenterol Hepatol 1:27–33.Google Scholar
  24. Börsch G, Mai U, Müller KM (1988a) Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease. Scand J Gastroenterol [Suppl 142] 23:101–106.Google Scholar
  25. Börsch G, Schmidt G, Wegener M, Sandmann M, Adamek R, Leverkus F, Reitemeyer E (1988b) Campylobacter pylori: prospective analysis of clinical and histological factors associated with colonization of the upper gastrointestinal tract. Eur J Clin Invest 18:133–138.PubMedGoogle Scholar
  26. Börsch G, Wegener M, Mai U, Opferkuch W (1989a) Efficiency of oral triple therapy to eradicate Campylobacter pylori. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, pp 595–598.Google Scholar
  27. Börsch G, Wegener M, Reitemeyer E, Mai U, Opferkuch W (1989b) Clinical results and medium term follow-up studies after eradication of Campylobacter pylori. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, pp 599–603.Google Scholar
  28. Buck GE, Gourley WK, Lee WK, Subramanyam K, Latimer JM, DiNuzzo AR (1986) Relation of Campylobacter pyloridis to gastritis and peptic ulcer. J Infect Dis 153:664–669.PubMedGoogle Scholar
  29. Burette A, Glupczynski Y, Jonas C, de Reuck M, van Gossum M, Deprez C, Tielemans C, Deltenre M (1986) Significance de la présence du Campylobacter pyloridis dans l’antre gastrique. Acta Gastroenterol Belg 49:70–83.PubMedGoogle Scholar
  30. Burette A, Glupczynski Y, Dereuck M, Labbe M, Deltenre M (1987) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial with amoxicillin (Abstr 28). 4th International Workshop on Campylobacter infections, Göteborg.Google Scholar
  31. Burette A, Glupczynski Y, Thibaumont F, Deprez C (1989) Evaluation of short-term amoxicillin/tinidazole combination in the treatment of Campylobacter pylori infection. Klin Wochenschr [Suppl 18] 67:7–8.Google Scholar
  32. Cadranel S, Glupczinsky Y, Labbe M, de Prez C (1988) Campylobacter pylori in children. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ (eds) Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 110–115.Google Scholar
  33. Coelho LGV, Queiroz DMM, Barbosa AJA, Mendes EN, Rocha GA, Oliveira CA, Lima GF Jr, Passos MCF, Castro LP (1989a) Campylobacter pylori, duodenal ulcer and furazolidone treatment. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, pp 611–614.Google Scholar
  34. Coelho LGV, Passos MCF, Queiroz DMM, Barbosa AJA, Mendes EN, Rocha GA, Oliveira CA, Lima GF Jr, Chausson Y, Castro LP (1989b) Five days triple therapy and 15 days double therapy on C. pylori eradication. Klin Wochenschr [Suppl 18] 67:11.Google Scholar
  35. Coghlan JG, Gilligan D, Humphreys H, McKenna D, Dooley C, Sweeney E, Keane C, O’Morain C (1987) Campylobacter pylori and recurrence of duodenal ulcers — a 12-month follow-up study. Lancet 2:1109–1111.PubMedGoogle Scholar
  36. Coghlan JG, Tobin A, O’Morain C (1989) Campylobacter pylori and ulcer treatment. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, pp 232–245.Google Scholar
  37. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. JAMA 261:3272–3277.Google Scholar
  38. Czinn SJ, Dahms BB, Jacobs GH, Kaplan B, Rothstein FC (1986) Campylobacter-like organisms in association with symptomatic gastritis in children. J Pediatr 109:80–83.PubMedGoogle Scholar
  39. Czinn S, Carr H, Sheffler L, Aronoff S (1989) Serum IgG antibody to the outer membrane proteins of Campylobacter pylori in children with gastroduodenal disease. J Infect Dis 159:586–589.PubMedGoogle Scholar
  40. De Koster E, Nyst J, Glupczynski Y, Burette A, Deprez C, van Gossum M, Deltenre M (1989a) Campylobacter pylori: results of one-week amoxicillin sachets + nitrofurantoin therapy. Klin Wochenschr [Suppl 18] 67:15–16.Google Scholar
  41. De Koster E, Nyst J, Glupczynski Y, Deprez C, de Reuck M, Deltenre M (1989b) Treatment of Campylobacter pylori: results of one-week amoxicillin sachets + tinidazole therapy. Klin Wochenschr [Suppl 18] 67:16.Google Scholar
  42. De Koster E, Nyst J, Glupczynski Y, Deprez C, Jonas C, Deltenre M (1989c) Amoxicillin + tinidazole vs amoxicillin + nitrofurantoin: tinidazole is a key drug in Campylobacter pylori treatment. Klin Wochenschr [Suppl 18] 67:16–17.Google Scholar
  43. Dickgießer N, Kasper GF, Manegold BC, Jung M, Raute-Kreinsen U (1987) Campylobacterähnliche Bakterien in der Magenschleimhaut. MMW. 129:420–423.Google Scholar
  44. Dobrilla G, Vallerta P, Amplatz S (1988) Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials. Gut 29:181–187.PubMedGoogle Scholar
  45. Dooley CP, Cohen H (1988) The clinical significance of Campylobacter pylori. Ann Intern Med 108:70–79.PubMedGoogle Scholar
  46. Dooley CP, McKenna D, Humphreys H, Bourke S, Keane CT, Sweeney E, O’Morain C (1988) Histologic gastritis in duodenal ulcer: relationship to Campylobacter pylori and effect of ulcer therapy. Am J Gastroenterol 83:278–282.PubMedGoogle Scholar
  47. Drumm B, Sherman P, Cutz E, Karmali M (1987) Association of Campylobacter pylori on the gastric mucosa with antral gastritis in children. N Engl J Med 316:1557–1561.PubMedGoogle Scholar
  48. Dwyer B, Kaldor J, Tee W, Marakowski E, Raios K (1988a) Antibody response to Campylobacter pylori in diverse ethnic groups. Scand J Infect Dis 20:349–350.PubMedGoogle Scholar
  49. Dwyer B, Nanxiong S, Kaldor J, Tee W, Lambert J, Luppino M, Flannery G (1988b) Antibody response to Campylobacter pylori in an ethnic group lacking peptic ulceration. Scand J Gastroenterol 20:63–68.Google Scholar
  50. Eastham EJ, Elliott TSJ, Berkeley D, Jones DM (1988) Campylobacter pylori infection in children. J Infect 16:77–79.PubMedGoogle Scholar
  51. Eberhardt R, Kasper G, Dettmer A, Höchter W, Hagena D (1988) Wirkung von Wismutsubsalicylat versus Cimetidin auf Campylobacter pylori, Ulkusheilung und-rezidivrate. Med Klin 83:402–405.Google Scholar
  52. Fauchère JL, Rosenau A, Bonneville F (1989) Virulence factors of Campylobacter pylori. Gastroenterol Clin Biol 13:59B–64B.PubMedGoogle Scholar
  53. Figura N, Guglielmetti P, Rossolini A, Barberi A, Cusi G, Musmanno RA, Russi M, Quaranta S (1989) Cytotoxin production by Campylobacter pylori strains isolated from patients with peptic ulcers and from patients with chronic gastritis only. J Clin Immunol 27:225–226.Google Scholar
  54. Gavey CJ, Szeto M-L, Nwokolo CU, Sercombe J, Pounder RE (1989) Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 3:21–28.PubMedGoogle Scholar
  55. Gilman R, Leon-Barua R, Ramirez-Ramos A, Morgan D, Recavarron S, Spira W, Watanabe P, Kraft W, Pearson A (1987) Efficacy of nitrofurans in the treatment of antral gastritis with Campylobacter pyloridis. Gastroenterology 92:1405.Google Scholar
  56. Glupczynski Y, Labbe M, Burette A, Delmee M, Avesani V, Bruck C (1987) Treatment failure of Ofloxacin in Campylobacter pylori infection. Lancet 1:1096.PubMedGoogle Scholar
  57. Glupczynski Y, Burette A, Labbe M, Deprez C, de Reuck M, Deltenre M (1988) Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxicillin. Am J Gastroenterol 83:365–372.PubMedGoogle Scholar
  58. Glupczynski Y, Burette A, Deprez C, Labbe M (1989a) Evaluation of non-absorbable antibiotics in Campylobacter pylori (CP)-associated gastritis. 5th International Workshop on Campylobacter Infections, Puerto Vallarta.Google Scholar
  59. Glupczynski Y, Nyst JF, Burette A, Vanderlinden MP, Deltenre M (1989b) Lack of antibiotic compliance in patients treated for Campylobacter pylori-associated gastritis. 5th International Workshop on Campylobacter Infections Puerto Vallarta.Google Scholar
  60. Goodwin CS (1988) Duodenal ulcer, Campylobacter pylori, and the “leaking roof” concept. Lancet 2:1467–1469.PubMedGoogle Scholar
  61. Goodwin CS, Armstrong JA, Marshall BJ (1986) Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol 39:353–365.PubMedGoogle Scholar
  62. Goodwin CS, Marshall BJ, Blincow ED, Wilson DH, Blackbourn S, Phillips M (1988) Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 41:207–210.PubMedGoogle Scholar
  63. Goodwin CS, Armstrong JA, Chilvers T, Peters M, Collins MD, Sly L, McConnell W, Harper WE (1989a) Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen nov as Helicobacter pylori comb nov and Helicobacter mustelae comb nov, respectively. Int J Syst Bacteriol 39:397–405.Google Scholar
  64. Goodwin CS, Bell B, McCullough C, Turner M (1989b) Sensitivity of Campylobacter pylori to colloidal bismuth subcitrate. J Clin Pathol 42:216–219.PubMedGoogle Scholar
  65. Graham DY (1989a) Campylobacter pylori as a pathogenic factor in duodenal ulcer: the case for. Scand J Gastroenterol [Suppl 160] 24:46–52.Google Scholar
  66. Graham DY (1989b) Campylobacter pylori and peptic ulcer disease. Gastroenterology 96:615–625.PubMedGoogle Scholar
  67. Graham DY (1990) Campylobacter pylori in human populations: the present and predictions of the future based on the epidemiology of polio. In: Menge H, Gregor M, McNulty CAM, Marshall BJ, Tytgat G (eds) 2nd International Symposium on Campylobacter pylori. Springer, Berlin Heidelberg New York (in press).Google Scholar
  68. Graham DY, Klein PD (1987) Campylobacter pyloridis gastritis: the past, the present, and speculations about the future. Am J Gastroenterol 82:283–286.PubMedGoogle Scholar
  69. Graham DY, Alpert LC, Lacey Smith J, Yoshimura HH (1988a) Iatrogenic Campylobacter pylori infection is a cause of epidemic hypochlorhydria. Am J Gastroenterol 83:974–980.PubMedGoogle Scholar
  70. Graham DY, Klein DP, Opekun AR, Boutton TW (1988b) Effect of age on the frequency of active Campylobacter pylori infection diagnosed by the (13C)urea breath test in normal subjects and patients with peptic ulcer disease. J Infect Dis 157:777–780.PubMedGoogle Scholar
  71. Graham DY, Adam E, Klein PD, Evans DJ Jr, Evans DG, Hazell SL, Alpert LC, Michaletz PA, Yoshimura HH (1989a) Epidemiology of Campylobacter pylori infection. Gastroenterol Clin Biol 13:84B–89B.PubMedGoogle Scholar
  72. Graham DY, Klein PD, Opekun AR, Smith KE, Polasani RR, Evans DJ Jr, Evans DG, Alpert JC, Michaletz PA, Yoshimura HH, Adam (1989b) In vivo susceptibility of Campylobacter pylori. Am J Gastroenterol 84:233–238.PubMedGoogle Scholar
  73. Graham DY, Lew GM, Michaletz PA (1989c) Randomized controlled trial of the effect of eradication of C. pylori on ulcer healing and relapse. Gastroenterology 96:A181.Google Scholar
  74. Hazell SL, Hennessy WB, Borody TJ, Carrick J, Ralston M, Brady L, Lee A (1987) Campylobacter pyloridis gastritis. II. Distribution of bacteria and associated inflammation in the gastroduodenal environment. Am J Gastroenterol 82:297–301.PubMedGoogle Scholar
  75. Hespe W, Staal HJM, Hall DWR (1988) Bismuth absorption from the colloidal subcitrate. Lancet 2:1258.PubMedGoogle Scholar
  76. Hirschl AM, Pletschette M (1989) Antibiotic treatment of Campylobacter pylori infection. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, pp 217–224.Google Scholar
  77. Hirschl AM, Stanek G, Rotter M, Hentschel E, Schütze K (1987a) Ulcus duodeni und Antibiotika-Therapie. Dtsch Med Wochenschr 112:781.PubMedGoogle Scholar
  78. Hirschl AM, Stanek G, Rotter M, Pötzi R, Gangl A, Hentschel E, Schütze K, Holzner HJ, Nemec H (1987c) Campylobacter pylori, Gastritis und Ulcus pepticum. Wien Klin Wochenschr 99:493–497.PubMedGoogle Scholar
  79. Hornick RB (1987) Peptic ulcer disease: a bacterial infection? N Engl J Med 316:1598–1600.PubMedGoogle Scholar
  80. Hui WM, Lam SK, Chau PY, Ho J, Lui I, Lai CL, Lok ASF, Ng MMT (1987) Persistence of Campylobacter pyloridis despite healing of duodenal ulcer and improvement of accompanying duodenitis and gastritis. Dig Dis Sci 32:1255–1260.PubMedGoogle Scholar
  81. Humphreys H, Bourke S, Dooley C, McKenna D, Power B, Keane CT, Sweeney EC, O’Morain C (1988) Effect of treatment on Campylobacter pylori in peptic disease: a randomised prospective trial. Gut 29:279–283.PubMedGoogle Scholar
  82. Jiang SJ, Liu WZ, Zhang DZ, Shi Y, Xiao SD, Zhang ZH, Lu DY (1987) Campylobacter-like organisms in chronic gastritis, peptic ulcer, and gastric carcinoma. Scand J Gastroenterol 22:553–558.PubMedGoogle Scholar
  83. Johnston BJ, Reed PI, Ali MH (1988) Prevalence of Campylobacter pylori in duodenal and gastric mucosa — relationship to inflammation. Scand J Gastroenterol [Suppl 142] 23:69–75.Google Scholar
  84. Jones DM, Lessells AM, Eldridge J (1984) Campylobacter-like organisms on the gastric mucosa: culture, histological, and serological studies. J Clin Pathol 37:1002–1006.PubMedGoogle Scholar
  85. Kalenic S, Falisevac V, Scukanec-Spoljar M, Gmajnicki B, Knezevic S, Vodopija I (1987) Ofloxacin and metronidazole activity on gastritis and peptic ulcer associated with Campylobacter pylori (Abstr 75). 4th International Workshop on Campylobacter Infections. Göteborg.Google Scholar
  86. Kilbridge PM, Dahms BB, Czinn SJ (1988) Campylobacter pylori-associated gastritis and peptic ulcer disease in children. Am J Dis Child 142:1149–1152.PubMedGoogle Scholar
  87. Klein PD, Graham DY (1989) Campylobacter pylori detection by the 13C-urea breath test. In: Rathbone B, Heatley V (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, pp 94–106.Google Scholar
  88. Klein PD, the Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities, Graham DY, Opekun AR, Sekeley S, Evans DG, Evans DJ Jr (1989) High prevalence of Campylobacter pylori (CP) infection in poor and rich peruvian children determined by 13C urea breath test (13C-UBT). Gastroenterology 96:A260.Google Scholar
  89. Koop H, Stumpf M, Eissele R, Lamberts R, Creutzfeld W, Arnold R (1989) Antral Campylobacter pylori in different states of gastric acid secretion. Gastroenterology 96:A267.Google Scholar
  90. Kosunen TU, Höök J, Rautelin HI, Myllylä G (1989) Age-dependent increase of Campylobacter pylori antibodies in blood donors. Scand J Gastroenterol 24:110–114.PubMedGoogle Scholar
  91. Krajden S, Anderson J, Kempston J, Fuksa M, Matlow A, Skoglund M, Bier D, Marcon N, Kortan P, Haber G, Babida C, Petrea C (1989) Effect of Pepto-Bismol (Bismuth subsalicylate, BSS) dose levels on C. pylori clearance. 5th International Workshop on Campylobacter Infections, Puerto Vallarta.Google Scholar
  92. Krakowka S, Morgan DR, Kraft WG, Leunk RD (1987) Establishment of gastric Campylobacter pylori infection in the neonatal gnotobiotic piglet. Infect Immun 55:2789–2796.PubMedGoogle Scholar
  93. Kristiansen JE, Justesen T, Hvidberg EF, Andersen LP (1989) Trimipramin and other antipsychotics inhibit Campylobacter pylori in vitro. Pharmacol Toxicol 64:386–388.PubMedGoogle Scholar
  94. Kurpad AV, Shetty (1986) Effects of antimicrobial therapy on faecal bulking. Gut 27:55–58.PubMedGoogle Scholar
  95. Lambert JR, Borromeo M, Korman MG, Hansky J, Eaves ER (1987) Effect of colloidal bismuth (De-Nol) on healing and relapse of duodenal ulcers — role of Campylobacter pyloridis. Gastroenterology 92:1489.Google Scholar
  96. Lambert JR, Borromeo M, Eaves ER, Hansky J, Korman M (1988) Efficacy of different dosage regimens of bismuth in eradicating Campylobacter pylori. Gastroenterology 94:A248.Google Scholar
  97. Lamouliatte H, Megraud F, de Mascarel A, Roux D, Quinton A (1987b) “Campylobacter pyloridis” and epigastric pain: endoscopic, histological, and bacteriological correlations. Gastroenterol Clin Biol 11:212–216.PubMedGoogle Scholar
  98. Lamouliatte H, Megraud F, de Mascarel A, Barberis C, Bernard PH, Cayla R, Quinton A (1989) Does omeprazole improve amoxicillin therapy directed against Campylobacter pyloridis-associated chronic gastritis? Klin Wochenschr [Suppl 18] 67:37.Google Scholar
  99. Lane MR, Lee SP (1988) Recurrence of duodenal ulcer after medical treatment. Lancet 1:1147–1149.PubMedGoogle Scholar
  100. Langenberg ML, Rauws EAJ, Schipper MEI, Widjojokosumo A, Tytgat GNJ, Rietra PJGM, Zanen HC (1985) The pathogenic role of Campylobacter pyloridis studied by attempts to eliminate these organisms. In: Pearson AD, Skirrow MB, Lior H, Rowe B (eds) Campylobacter III. PHLS, London, pp 162–163.Google Scholar
  101. Langenberg W, Rauws EAJ, Widjojokusumo A, Tytgat GNJ, Zanen HC (1986) Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol 24:414–417.PubMedGoogle Scholar
  102. Langenberg W, Rauws EAJ, Houthoff HJ, Oudbier J, Tytgat GJN, Zanen HC (1987) Follow-up of C. pylori-associated gastritis (CPG) after treatment with amoxicillin and/or colloidal bismuth (Abstr 94). 4th International workshop on Campylobacter infections, Göteborg.Google Scholar
  103. Langenberg W, Rauws EAJ, Houthoff HJ, Oudbier JH, van Bohemen CG, Tytgat GNJ, Rietra PJGM (1988) Follow-up study of individuals with untreated Campylobacter pylori-associated gastritis and of noninfected persons with non-ulcer dyspepsia. J Infect Dis 157:1245–1249.PubMedGoogle Scholar
  104. Mahoney MJ, Littlewood JM (1989) Campylobacter pylori in paediatric population. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, pp 167–175.Google Scholar
  105. Mahoney MJ, Wyatt JI, Littlewood JM (1988) Campylobacter pylori gastritis. Arch Dis Child 63:654–655.Google Scholar
  106. Mainguet P, Delmée M, Debongnie J-C (1989) Omeprazole, Campylobacter pylori, and duodenal ulcer. Lancet 2:389–390.PubMedGoogle Scholar
  107. Malfertheiner P, Bode G, Vanek E, Stanescu A, Lutz E, Blessing J, Ditschuneit H (1987) Campylobacter pylori — besteht ein Zusammenhang mit der peptischen Ulcuskrankheit? Dtsch Med Wochenschr 112:493–497.PubMedGoogle Scholar
  108. Malfertheiner P, Stanescu A, Baczako K, Vanek E, Bode G, Ditschuneit H (1988) Wismutsubsalicylat-Behandlung bei Campylobacter-pylori-assoziierter chronischer erosiver Gastritis. Dtsch Med Wochenschr 113:923–929.PubMedGoogle Scholar
  109. Malfertheiner P, Bode G, Stanescu A, Ditschuneit H (1989) Gastric metaplasia and Campylobacter pylori in duodenal ulcer disease: an ultrastructural analysis. Gastroenterol Clin Biol 13:71B–74B.PubMedGoogle Scholar
  110. Mannes GA, Bayerdörffer E, Höchter W, Weingart J, Heldwein W, Müller-Lissner S, Oertel H, Blendinger C, Kuntzen O, Bornschein W, Malfertheiner P, Wilkening J, Ruckdeschel G, Pfaller P, von Wulffen H, Köpcke W, Stolte M (1989) Early relapse rate after healing of C. pylori-positive duodenal ulcers. Klin Wochenschr [Suppl 18] 67:44.Google Scholar
  111. Marcheggiano A, Iannoni C, Agnello M, Paoluzi P, Pallone F (1987) Campylobacter-like organisms on the human gastric mucosa. Relation to type and extent of gastritis in different clinical groups. Gastroenterol Clin Biol 11:376–381.PubMedGoogle Scholar
  112. Marshall BJ (1986) Campylobacter pyloridis and gastritis. J Infect Dis 153:650–657.PubMedGoogle Scholar
  113. Marshall BJ (1989) Antimicrobial therapy of duodenal ulcer? Hold off for now. Reply. Gastroenterology 97:510.Google Scholar
  114. Marshall BJ, Warren JR (1984) Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1:1311–1315.PubMedGoogle Scholar
  115. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ (1985) Attempt to fulfil Koch’s postulates for pyloric Campylobacter. Med J Aust 142:436–439.PubMedGoogle Scholar
  116. Marshall BJ, Armstrong JA, Francis GJ, Nokes NT, Wee SH (1987) Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis. Digestion [Suppl 2] 37:16–30.Google Scholar
  117. Marshall BJ, Goodwin CS, Warren JR, Murray R, Blincow ED Blackbourn SJ, Phillips M, Waters TE, Sanderson CR (1988) Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 2:1437–1442.PubMedGoogle Scholar
  118. Marshall BJ, Barret LJ, McCallum RW, Guerrant RL (1989a) C. pylori therapy: is in vitro disc testing with metronidazole worthwhile? 5th International Workshop on Campylobacter Infections, Puerto Vallarta.Google Scholar
  119. Marshall BJ, Caldwell SH, Hoffman SR, Frierson HF, Guerrant RL, McCallum RW (1989b) Can C. pylori be eradicated? Long-term follow-up on 28 successfully treated patients. Gastroenterology 96:A321.Google Scholar
  120. Marshall BJ, Caldwell SH, Yu ZJ, Darr F, Chang T, McCallum RW (1989c) Prevalence of C. pylori and history of upper GI investigation in healthy Virginians. Gastroenterology 96:A321.Google Scholar
  121. McColl KEL, Fullarton GM, El Nujumi AM, MacDonald AM, Brown IL, Hilditch TE (1989) Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer. Lancet 2:499–500.PubMedGoogle Scholar
  122. McLean AJ, Harcourt DM, McNeil JJ (1988) Relapse rate as a major determinant of drug selection in peptic ulcer disease. Drugs 35:329–333.PubMedGoogle Scholar
  123. McNulty CAM (1989) Bacteriological and pharmacological basis for the treatment of Campylobacter pylori infection. Gastroenterol Clin Biol 13:96B–100B.PubMedGoogle Scholar
  124. McNulty CAM, Gearty JC, Crump B, Davis M, Donovan IA, Melikian V, Lister DM, Wise R (1986) Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J 293:645–649.Google Scholar
  125. McNulty CAM, Dent JC, Ford GA, Wilkinson SP (1988) Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 22:729–738.PubMedGoogle Scholar
  126. McNulty CAM, Eyre-Brook IA, Uff JS, Dent JC, Wilkinson SP (1989) Triple therapy is not always 95% effective. 5th International Workshop on Campylobacter Infections, Puerto Vallarta.Google Scholar
  127. Menge H (1988) Was ist gesichert in der Behandlung der Campylobacter-pylori-induzierten Gastritis und des Campylobacter-pylori-assoziierten peptischen Ulkus? Internist (Berlin) 29:745–754.Google Scholar
  128. Menge H, Hofmann J, Gregor M (1987a) Dosis-Wirkungs-Studien mit Wismutsalzen zur Elimination von Campylobacter pylori. Z Gastroenterol [Suppl 4] 25:44–46.Google Scholar
  129. Menge H, Warreimann M, Loy V, Schmidt H, Gregor M, Skubis R, Hahn H, Riecken EO (1987b) Erste prospektiv erhobene Befunde zum Vorkommen von Campylobacter pyloridis in der menschlichen Antrumschleimhaut in der Bundesrepublik Deutschland. Med Klin 82:23–25.Google Scholar
  130. Menge H, Hoffmann J, Boenigk U, Gregor M (1988) Attempts to eradicate Campylobacter pylori — German experiences. In: Menge H, Gregor M, Tytgat GNJ, Marshall BJ (eds) Campylobacter pylori. Springer, Berlin Heidelberg New York, pp 228–230.Google Scholar
  131. Mertens JCC, Dekker W, Ligtvoet EEJ, Blok P (1989) Treatment failure of norfloxacin against Campylobacter pylori and chronic gastritis in patients with nonulcerative dyspepsia. Antimicrob Agents Chemother 33:256–257.PubMedGoogle Scholar
  132. Miller JP, Faragher EB (1986) Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? Br Med J 293:1117–1118.Google Scholar
  133. Mitchell HM, Lee A, Berkowicz, J, Borody T (1988) The use of serology to diagnose active Campylobacter pylori infection. Med J Aust 149:604–609.PubMedGoogle Scholar
  134. Morgan D, Kraft W, Bender M, Pearson A and the Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities (1988) Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 95:1178–1184.PubMedGoogle Scholar
  135. Morris A, Nicholson G (1987) Ingestion of Campylobacter pyloridis causes gastritis and raised fasting gastric pH. Am J Gastroenterol 82:192–199.PubMedGoogle Scholar
  136. Morris A, Arthur J, Nicholson G (1986) Campylobacter pyloridis infection in Auckland patients with gastritis. N Z Med J 99:353–355.PubMedGoogle Scholar
  137. Niemelä S, Karttunen T, Lehtola J (1987) Campylobacter-like organisms in patients with gastric ulcer. Scand J Gastroenterol 22:487–490.PubMedGoogle Scholar
  138. Nwokolo CU, Gavey CJ, Smith JTL, Pounder RE (1989) The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 3:29–39.PubMedGoogle Scholar
  139. Oderda G, dell’olio D, Morra I, Ansaldi N (1989a) Campylobacter pylori gastritis: long term results of treatment with amoxicillin. Arch Dis Child 64:326–329.PubMedGoogle Scholar
  140. Oderda G, Vaira D, Hoton J, Ainley C, Altare F, Ansaldi N (1989b) Amoxicillin plus tinidazole for Campylobacter pylori gastritis in children: assessment by serum IgG antibody, pepsinogen I, and gastrin levels. Lancet 1:690–692.PubMedGoogle Scholar
  141. O’Riordan T, Tobin A, Beattie S, Sweeney E, Keane C, O’Morain C (1989) Adjuvant antibiotic treatment improves eradication of Campylobacter pylori in duodenal ulcer. Gastroenterology 96:A378.Google Scholar
  142. Patey O, Chaplain C, Dublanchet A, Malkin JE, Roucayrol AM, Charasz N (1989) Failure of treatment with metronidazole for Campylobacter pylori infection. In: Mégraud F, Lamouliatte H (eds) Campylobacter pylori and gastroduodenal pathology. Elsevier Amsterdam, pp 629-632.Google Scholar
  143. Paulsen O, Höglund P, Walder M (1989) No effect of omeprazole-induced hypoacidity on the bioavailability of amoxicillin or bacampicillin. Scand J Infect Dis 21:219–223.PubMedGoogle Scholar
  144. Perez-Perez GI, Dworkin BM, Chodos JE, Blaser MJ (1988) Campylobacter pylori antibodies in humans. Ann Intern Med 109:11–17.PubMedGoogle Scholar
  145. Price AB, Levi J, Dolby JM, Dunscombe PL, Smith A, Clark J, Stephenson ML (1985) Campylobacter pyloridis in peptic ulcer disease: microbiology, pathology, and scanning electron microscopy. Gut 26:1183–1188.PubMedGoogle Scholar
  146. Rao SSC, Edwards CA, Austen CJ, Bruce C, Read NW (1988) Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 94:928–932.PubMedGoogle Scholar
  147. Raskov H, Lanng C, Gaarslev K, Fischer Hansen B (1987) Screening for Campylobacter pyloridis in patients with upper dyspepsia and the relation to inflammation of the human gastric antrum. Scand J Gastroenterol 22:568–572.PubMedGoogle Scholar
  148. Rathbone BJ, Heatley RV (1989) Possible pathogenic mechanisms in Campylobacter pylori infection. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell, Oxford, pp 203.Google Scholar
  149. Rathbone BJ, Wyatt JI, Heatley RV (1986) Campylobacter pyloridis — a new factor in peptic ulcer disease. Gut 27:635–641.PubMedGoogle Scholar
  150. Rathbone BJ, Wyatt JI, Heatley RV (1988) Possible pathogenetic pathways of Campylobacter pylori in gastroduodenal disease. Scand J Gastroenterol [Suppl 142] 23:40–43.Google Scholar
  151. Rathbone BJ, Wyatt JI, Heatley RV (1989) Local response of the host to Campylobacter pylori. Gastroenterol Clin Biol 13:75B–77B.PubMedGoogle Scholar
  152. Rauws EAJ (1989) Long term follow-up of Campy lobacter pylori-associated gastritis after treatment with colloidal bismuth subcitrate and/or amoxicillin. In: Mégraud F, Lamouliatte H (eds) Campylobacter pylori and gastroduodenal pathology. Elsevier, Amsterdam, pp 633–636.Google Scholar
  153. Rauws EAJ, Tytgat GN (1987) Elektronenmikroskopische Befunde während einer Behandlung Campylobacter-pylori-positiver Gastritiden mit Wismutsalzen. Z Gastroenterol [Suppl 4] 25:41–43.Google Scholar
  154. Rauws EAJ, Tytgat GN (1989) Campylobacter pylori: treatment of gastritis. In: Rathbone BJ, Heatley RV (eds) Campylobacter pylori and gastroduodenal disease. Blackwell Oxford, pp 225-231.Google Scholar
  155. Rauws EAJ, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN (1988) Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effect of antibacterial and antiulcer treatment. Gastroenterology 94:33–40.PubMedGoogle Scholar
  156. Rogé J, Bloch F, Camilleri JP, Tricottet V, Lambert N, Proux MC (1986) Antrites érosives chroniques et “Campylobacter pyloridis” — étude histologique et ultrastructurale. Sem Hōp Paris 62:81–89.Google Scholar
  157. Rollason TP, Stone J, Rhodes JM (1984) Spiral organisms in endoscopic biopsies of the human stomach. J Clin Pathol 37:23–26.PubMedGoogle Scholar
  158. Rösch W, Becker V, Steininger H, Menge H (1989) Campylobacter-pylori-assoziierte Gastritis. Therapie mit Wismutsubsalizylat. MMW 130:97–100.Google Scholar
  159. Rosenblatt JE, Edson RS (1987) Metronidazole. Mayo Clin Proc 62:1013–1027.PubMedGoogle Scholar
  160. Sabbatini F, d’Arienzo A, Piai G, Verre C, Ciacci C, d’Argenio G, Minieri M, Sapio E, Mazzacca G (1989) Influence of blood group and secretor status on Campylobacter pylori infection. Gastroenterology 96:A433.Google Scholar
  161. Saxon A, Beall GN, Rohr AS, Aldeman DC (1987) Immediate hypersensitivity reactions to betalactam antibiotics. Ann Intern Med 107:204–215.PubMedGoogle Scholar
  162. Scarpignato C, Galmiche J-P (1988) Mucosal coating agents: pharmacology and clinical use. In: Bianchi Porro G (ed) Topics in digestive disease. Raven, New York, pp 73–133.Google Scholar
  163. Schaub N, Stalder H, Stalder GA, Affolter H, Wegmann W (1987) Versagen von Doxycyclin bei Campylobacter-pylori-positiver Gastritis. Dtsch Med Wochenschr 112:117–118.PubMedGoogle Scholar
  164. Scully BE (1988) Metronidazole. Med Clin North Am 72:613–621.PubMedGoogle Scholar
  165. Simor AE, Ferro S, Low DE (1989) Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori. Antimicrob Agents Chemother 33:108–109.PubMedGoogle Scholar
  166. Sipponen P (1990) Risk of peptic ulcer in gastritis. In: Malfertheimer P, Ditschuneit H (eds) Helicobacter pylori, gastritis and peptic ulcer. Springer, Berlin Heidelberg New York Tokyo, pp 223–227. Symposium on Campylobacter pylori. Springer, Berlin Heidelberg New York (in press).Google Scholar
  167. Smith AC, Price AB, Borriello P, Levi AJ (1988) A comparison of ranitidine and tripotasssium dicitrato-bismuth (T.D.B.) in relapse rates of duodenal ulcer. The role of Campylobacter pylori (C.P.) Gastroenterology 94:A431.Google Scholar
  168. Stadler P, Blum AL (1989) Ist Campylobacter pylori der Erreger der Ulkuskrankheit? Contra. Z Gastroenterol 27:127–130.PubMedGoogle Scholar
  169. Steer HW (1985) The gastroduodenal epithelium in peptic ulceration. J Pathol 146:355–362.PubMedGoogle Scholar
  170. Steininger H, Schneider U, Bartz K, Simmler B (1989) Campylobacter pylori und Gastritis — Besiedelungsdichte und Grad der Entzündung. Semiquantitative und morphometrische Untersuchung. Leber Magen Darm 19:70–78.PubMedGoogle Scholar
  171. Stolte M, Eidt S, Ritter M, Bethke B (1989) Campylobacter pylori und Gastritis. Assoziation oder Induktion? Pathologe 10:21–26.PubMedGoogle Scholar
  172. Stone JW, Wise R, Donovan IA, Gearty J (1988) Failure of Ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother 22:92–93.PubMedGoogle Scholar
  173. Taylor DE, Hargreaves JA, Lai-King NG, Sherbaniuk W, Jewell LD (1987) Isolation and characterization of Campylobacter pyloridis from gastric biopsies. Am J Clin Pathol 87:49–54.PubMedGoogle Scholar
  174. Tytgat GNJ (1987) Colloidal bismuth subcitrate in peptic ulcer — a review. Digestion [Suppl 2] 37:31–41.Google Scholar
  175. Tytgat GNJ, Rauws EAJ (1987) Significance of Campylobacter pylori. Aliment Pharmacol Ther 1:527S–539S.PubMedGoogle Scholar
  176. Tytgat GNJ, Rauws A (1989) The role of Campylobacter pylori in gastroduodenal disease. A “believer”’ s point of view. Gastroenterol Clin Biol 13:118B–121B.PubMedGoogle Scholar
  177. Von Wulffen H, Heesemann J, Bützow G, Löning T, Laufs R (1986) Detection of Campylobacter pyloridis in patients with antrum gastritis and peptic ulcers by culture, complement fixation test, and immunoblot. J Clin Microbiol 24:716–720.Google Scholar
  178. Wagner S, Freise J, Bär W, Fritsch S, Schmidt FW (1989) Epidemiologie und Therapie der Campylobacter-pylori-Infektion. Dtsch Med Wochenschr 114:407–413.PubMedGoogle Scholar
  179. Wagstaff AJ, Benfield P, Monk JP (1988) Colloidal bismuth subcitrate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 36:132–157.PubMedGoogle Scholar
  180. Weil J, Bell GD, Jones PH, Gant P, Trowell JE, Harrison G (1988) “Eradication” of Campylobacter pylori: are we being misled? Lancet 2:1245.PubMedGoogle Scholar
  181. Weil J, Bell GD, Harrison G, Trowell JE, Gant P, Jones PH (1989) Campylobacter pylori survive high doses bismuth sub-citrate (De-Nol) therapy. In: Mégraud F, Lamouliatte H (eds) Gastroduodenal pathology and Campylobacter pylori. Elsevier, Amsterdam, pp 651–653.Google Scholar
  182. Wright AJ, Wilkowske CJ (1987) The penicillins. Mayo Clin Proc 62:806–820.PubMedGoogle Scholar
  183. Wyatt JI, Dixon MF (1988) Chronic gastritis — a pathogenetic approach. J Pathol 154:113–124.PubMedGoogle Scholar
  184. Wyatt JI, Rathbone BJ (1988) Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol [Suppl 142] 23:44–49.Google Scholar
  185. Wyatt JI, Rathbone BJ (1989) Gastric metaplasia in the duodenum and Campylobacter pylori. Gastroenterol Clin Biol 13:78B–82B.PubMedGoogle Scholar
  186. Wyatt JI, Rathbone BJ, Dixon MF, Heatley RV (1987) Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis. J Clin Pathol 40:841–848.PubMedGoogle Scholar
  187. Wyatt JI, Rathbone BJ, Heatley RV, Losowsky MS (1988) Campylobacter pylori and history of dyspepsia in healthy blood donors. Gut 29:706.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • G. M. A. Börsch
  • D. Y. Graham

There are no affiliations available

Personalised recommendations